Facebook Twitter LinkedIn Google Plus RSS

CorMedix to raise $3M in concurrent offerings

By

Bridgewater-based pharmaceutical company CorMedix announced today it has entered into two securities purchase agreements with existing institutional investors.

According to the announcement, the company entered into a securities purchase agreement with an existing institutional investor, pursuant to which it has agreed to sell 150,000 shares of series C-1 nonvoting convertible preferred stock and a warrant to purchase up to 750,000 shares of common stock.

CorMedix also entered a separate securities purchase agreement with another existing institutional investor, pursuant to which it has agreed to sell 150,000 shares of series C-2 nonvoting convertible preferred stock and a warrant to purchase up to 750,000 shares of common stock, for aggregate gross proceeds of $3 million.

Write to the Editorial Department at editorial@njbiz.com

Related Stories

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close
Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!